Items where authors include "Burton, C"

Article

Davies, AJ, Barrans, S, Stanton, L et al. (20 more authors) (2023) Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up. Journal of Clinical Oncology, 41 (15). pp. 2718-2723. ISSN 0732-183X

Bewicke-Copley, F, Korfi, K, Araf, S et al. (33 more authors) (2023) Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma. Blood Advances, 7 (5). pp. 845-855. ISSN 2473-9529

Frood, R orcid.org/0000-0003-2681-9922, Clark, M, Burton, C et al. (5 more authors) (2022) Utility of pre-treatment FDG PET/CT-derived machine learning models for outcome prediction in classical Hodgkin lymphoma. European Radiology, 32 (10). pp. 7237-7247. ISSN 0938-7994

Frood, R orcid.org/0000-0003-2681-9922, Clark, M, Burton, C et al. (5 more authors) (2022) Discovery of Pre-Treatment FDG PET/CT-Derived Radiomics-Based Models for Predicting Outcome in Diffuse Large B-Cell Lymphoma. Cancers, 14 (7). 1711. ISSN 2072-6694

Frood, R orcid.org/0000-0003-2681-9922, Burton, C, Tsoumpas, C orcid.org/0000-0002-4971-2477 et al. (4 more authors) (2021) Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review. European Journal of Nuclear Medicine and Molecular Imaging, 48 (10). pp. 3198-3220. ISSN 1619-7070

Ahmed, S orcid.org/0000-0003-4912-746X, Glover, P, Taylor, J et al. (8 more authors) (2021) Comparative analysis of gene expression platforms for cell‐of‐origin classification of diffuse large B‐cell lymphoma shows high concordance. British Journal of Haematology, 192 (3). bjh.17246. pp. 599-604. ISSN 0007-1048

Cucco, F, Barrans, S, Sha, C et al. (21 more authors) (2020) Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit. Leukemia, 34. pp. 1329-1341. ISSN 0887-6924

Painter, D, Barrans, S, Lacy, S et al. (8 more authors) (2019) Cell‐of‐origin in diffuse large B‐cell lymphoma: findings from the UK's population‐based Haematological Malignancy Research Network. British Journal of Haematology, 185 (4). pp. 781-784. ISSN 0007-1048

Davies, A, Cummin, TE, Barrans, S et al. (21 more authors) (2019) Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. The Lancet Oncology, 20 (5). pp. 649-662. ISSN 1470-2045

Sha, C, Barrans, S, Cucco, F et al. (20 more authors) (2019) Molecular high-grade B cell lymphoma: defining a poor risk group requiring different approaches to therapy. Journal of Clinical Oncology, 37 (3). pp. 202-213. ISSN 0732-183X

Rifai, SW, Girardin, CAJ, Berenguer, E et al. (37 more authors) (2018) ENSO Drives interannual variation of forest woody growth across the tropics. Philosophical Transactions of the Royal Society B: Biological Sciences, 373 (1760). rstb20170410. ISSN 0962-8436

Chasty, B, Patterson, M, Murray, LJ orcid.org/0000-0003-0658-6455 et al. (5 more authors) (2018) Lack of effectiveness of routine clinic and blood test-based follow-up for diffuse large B cell lymphoma. British Journal of Haematology, 182 (1). pp. 138-140. ISSN 0007-1048

Smith, A, Howell, D, Crouch, S et al. (10 more authors) (2018) Cohort Profile: The Haematological Malignancy Research Network (HMRN): a UK population-based patient cohort. International Journal of Epidemiology, 47 (3). 700-700g. ISSN 0300-5771

Rycroft-Malone, J, Burton, C, Wilkinson, J et al. (10 more authors) (2015) Collective action for knowledge mobilisation: a realist evaluation of the Collaborations for Leadership in Applied Health Research and Care. Health Services and Delivery Research, 3 (44).